| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.6 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.033 | 0.6 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |